Skin Cancer Drugs Market worth $~6 billion by 2027
The report "Skin Cancer Drugs Market by Type (Chemotherapy, Immunotherapy), Disease Indication (Melanoma, Basal and Squamous), Distribution Channel – Global Forecast to 2027", is projected to reach USD ~6 billion by 2027 from USD 4 billion in 2022, at a CAGR of 9 % during the forecast period
View detailed Table of Content here - https://www.marketsandmarkets.com/Market-Reports/skin-cancer-drugs-market-257714391.html
Factors such as rising incidence of different skin cancer conditions, the increasing popularity of advanced drugs for skin cancer treatment coupled with growing geriatric population are expected to support the growth of the skin cancer drugs market.
The melanoma segment accounted for the largest share of the skin cancer drugs market in 2021.
Based on the disease indication, the market is segmented into melanoma, basal and squamous cell skin cancer, and others. In 2021, the melanoma segment accounted for the largest share of the skin cancer drugs market. Growing drug approvals for melanoma is the key factor driving the growth of this market.
North America to command the largest share of the skin cancer drugs market in 2021
Based on region, the skin cancer drugs market is segmented into North America, Europe, the Asia Pacific, Rest of the World which includes the Latin America and Middle East & Africa. North America accounted for the largest share of the market in 2021. The growth of the North American market is primarily driven by the increased prevalence of skin cancer in the region.
Prominent players in the skin cancer drugs market include Novartis AG, Bristol Myers Squibb, Eli Lilly, Meda, Sun Pharmaceutical Industries Ltd, Roche, Aqua Pharmaceuticals, Bausch Health, GlaxoSmithKline PLC, and Pfizer Inc, among others.
About MarketsandMarkets™
MarketsandMarkets™ provides quantified B2B research on 30,000 high growth niche opportunities/threats which will impact 70% to 80% of worldwide companies’ revenues. Currently servicing 7500 customers worldwide including 80% of global Fortune 1000 companies as clients. Almost 75,000 top officers across eight industries worldwide approach MarketsandMarkets™ for their painpoints around revenues decisions.
Our 850 fulltime analyst and SMEs at MarketsandMarkets™ are tracking global high growth markets following the "Growth Engagement Model – GEM". The GEM aims at proactive collaboration with the clients to identify new opportunities, identify most important customers, write "Attack, avoid and defend" strategies, identify sources of incremental revenues for both the company and its competitors. MarketsandMarkets™ now coming up with 1,500 MicroQuadrants (Positioning top players across leaders, emerging companies, innovators, strategic players) annually in high growth emerging segments. MarketsandMarkets™ is determined to benefit more than 10,000 companies this year for their revenue planning and help them take their innovations/disruptions early to the market by providing them research ahead of the curve.
MarketsandMarkets’s flagship competitive intelligence and market research platform, "Knowledgestore" connects over 200,000 markets and entire value chains for deeper understanding of the unmet insights along with market sizing and forecasts of niche markets.
Contact:
Mr. Aashish Mehra
MarketsandMarkets™ INC.
630 Dundee Road
Suite 430
Northbrook, IL 60062
USA : 1-888-600-6441
sales@marketsandmarkets.com
- Triangulate with your Own Data
- Get Data as per your Format and Definition
- Gain a Deeper Dive on a Specific Application, Geography, Customer or Competitor
- Any level of Personalization
- What are the Known and Unknown Adjacencies Impacting the Skin Cancer Drugs Market
- What will your New Revenue Sources be?
- Who will be your Top Customer; what will make them switch?
- Defend your Market Share or Win Competitors
- Get a Scorecard for Target Partners
